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background
We examined whether a fixed dose of both isosorbide dinitrate and hydralazine pro-
vides additional benefit in blacks with advanced heart failure, a subgroup previously
noted to have a favorable response to this therapy.
methods
A total of 1050 black patients who had New York Heart Association class III or IV heart
failure with dilated ventricles were randomly assigned to receive a fixed dose of isosor-
bide dinitrate plus hydralazine or placebo in addition to standard therapy for heart fail-
ure. The primary end point was a composite score made up of weighted values for death
from any cause, a first hospitalization for heart failure, and change in the quality of life.
results
The study was terminated early owing to a significantly higher mortality rate in the pla-
cebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent
vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better
in the group given isosorbide dinitrate plus hydralazine than in the placebo group
(¡0.1±1.9 vs. ¡0.5±2.0, P=0.01; range of possible values, –6 to +2), as were its individ-
ual components (43 percent reduction in the rate of death from any cause [hazard ratio,
0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart
failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of
life [change in score, ¡5.6±20.6 vs. ¡2.7±21.2, with lower scores indicating better qual-
ity of life; P=0.02; range of possible values, 0 to 105]).
conclusions
The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy
for heart failure including neurohormonal blockers is efficacious and increases survival
among black patients with advanced heart failure.
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eurohormonal inhibitors alone
or in combination slow the progression
of left ventricular dysfunction, retarding
the structural remodeling of the left ventricle that
characterizes chronic heart failure and reducing the
rates of death and complications among patients
with heart failure.1-10 Endothelial dysfunction, im-
paired bioavailability of nitric oxide, and increased
oxidant stress also occur in patients with conges-
tive heart failure and contribute to the remodeling
process in experimental and clinical models of heart
failure.11-27 Augmentation of nitric oxide may there-
fore be an alternative or supplemental approach to
slow or reverse progressive heart failure. The first
Vasodilator Heart Failure Trial (V-HeFT I)6 demon-
strated the benefit of combining the nitric oxide
donor isosorbide dinitrate with the antioxidant hy-
dralazine in patients with mild-to-severe heart fail-
ure; however, the potential long-term benefit of this
therapy in patients treated with neurohormonal in-
hibitors has not been evaluated.
Differences exist in the prevalence and causation
of congestive heart failure and in the associated
morbidity and mortality, consistent with popula-
tion-based variations in the mechanisms of heart
failure.28-30 Studies have suggested that persons
who identify themselves as black may have, on aver-
age, a less active renin–angiotensin system29,31 and
a lower bioavailability of nitric oxide than those self-
identified as white.32-37 Retrospective analyses of
the databases of previous heart-failure trials38,39
strongly suggested that black patients have a clini-
cally significant response to a combination of iso-
sorbide dinitrate and hydralazine. On the basis of
these observations, we evaluated the efficacy of a
fixed dose of isosorbide dinitrate plus hydralazine
in black patients who had New York Heart Associa-
tion (NYHA) class III or IV heart failure with dilated
ventricles and who were receiving background ther-
apy that included neurohormonal blockers. 
study design
The African-American Heart Failure Trial (A-HeFT)
was a randomized, placebo-controlled, double-
blind trial with patients recruited at 161 centers in
the United States. The study protocol was reviewed
and approved by the institutional review board at
each site. All patients gave written informed con-
sent. Site monitoring, data collection, and data
management were performed by Medifacts Inter-
national, a clinical research organization. Data
analysis was performed by independent statisticians
and by Virtu Stat. The study sponsor was NitroMed.
Independent committees adjudicated all primary
and secondary end points, reviewed data on safety,
and oversaw the two prespecified interim analyses,
which were performed solely to assess the adequa-
cy of the sample size. The manuscript was prepared
by the authors and reviewed by the steering com-
mittee and the sponsor. The study design has been
described previously.40,41
inclusion and exclusion criteria
Patients 18 years of age or older, self-identified as
black (defined as of African descent), who had had
NYHA class III or IV heart failure for at least three
months were eligible for screening. Patients were
required to have been receiving standard therapy for
heart failure, as determined to be appropriate by
their physicians; such therapy included angioten-
sin-converting–enzyme inhibitors, angiotensin-
receptor blockers, beta-blockers for at least three
months before randomization, digoxin, spironolac-
tone, and diuretics. Patients also had to have evi-
dence of left ventricular dysfunction within the six
months preceding randomization in the form of a
resting left ventricular ejection fraction of no more
than 35 percent or a resting left ventricular ejection
fraction of less than 45 percent with a left ventric-
ular internal end-diastolic diameter of more than
2.9 cm per square meter of body-surface area or
more than 6.5 cm on the basis of echocardiography.
Women were excluded if they were pregnant,
nursing, or of childbearing age and not using an ef-
fective method of contraception. The following were
also reasons for exclusion: an acute myocardial in-
farction, acute coronary syndrome, or stroke within
the preceding three months; cardiac surgery or per-
cutaneous coronary intervention within the preced-
ing three months or the likelihood of a requirement
for such procedures during the study period; the
presence of clinically significant valvular heart dis-
ease, hypertrophic or restrictive cardiomyopathy,
active myocarditis, or uncontrolled hypertension;
a history of cardiac arrest or life-threatening arrhyth-
mias within the preceding three months (unless
they had been treated with an implantable defibril-
lator); treatment with parenteral inotropic agents
within one month before randomization; a poten-
tial need for cardiac transplantation; the presence
of symptomatic hypotension; the presence of an ill-
ness other than heart failure that was likely to result
n
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in death within the study period; an inability to com-
plete the quality-of-life questionnaire; and contrain-
dications to the use of nitrate or hydralazine therapy.
randomization procedure 
Randomization was performed centrally by Medi-
facts International, with stratification according to
the use or nonuse of beta-blockers as background
therapy. Blocks of 4 patients per stratum were used,
with each site allowed to randomize up to 6 blocks
of patients (24 patients) in the non–beta-blocker
group and up to 10 blocks (40 patients) in the beta-
blocker group.
Eligible patients were required to be receiving
stable doses of therapy for heart failure and to have
had a variation in body weight of less than 2.5 per-
cent in the two weeks before randomization. At ran-
domization, baseline evaluations included echocar-
diography, a metabolic profile, measurement of
B-type natriuretic peptide and hemoglobin levels,
and a quality-of-life questionnaire. After stratifica-
tion according to the use or nonuse of beta-block-
ers as background therapy, patients were randomly
assigned to receive a fixed-dose combination of iso-
sorbide dinitrate plus hydralazine or to receive pla-
cebo, each in addition to background therapy. The
initial dose was one tablet containing either place-
bo alone or 37.5 mg of hydralazine hydrochloride
and 20 mg of isosorbide dinitrate three times daily.
The dose was increased to two tablets three times
daily, for a total daily dose of 225 mg of hydralazine
hydrochloride and 120 mg of isosorbide dinitrate.
An increase in the dose was dependent on the ab-
sence of drug-induced side effects as judged by the
investigator. Patients were followed for up to 18
months, with assessment of the left ventricular ejec-
tion fraction, left ventricular internal diastolic di-
mension, left ventricular wall thickness, and level
of B-type natriuretic peptide at 6 months and as-
sessment of the quality of life every 3 months. Pa-
tients were interviewed by telephone monthly and
returned for follow-up visits every three months.
outcome measures
The primary efficacy end point for the trial was a
composite score made up of weighted values for
death from any cause, a first hospitalization for
heart failure during the 18-month follow-up period,
and change in the quality of life at 6 months. The
quality of life was assessed by means of the Minne-
sota Living with Heart Failure questionnaire, a 21-
question self-administered instrument in which
scores can range from 0 to 5 for each question, and
higher scores indicate a poorer quality of life.42 The
composite scoring system is shown in Table 1. 
Secondary end points included individual com-
ponents of the primary composite score, death from
cardiovascular causes, the total number of hospital-
izations for heart failure, the total number of hospi-
talizations for any reason, the total number of days
of hospitalization, the overall quality of life through-
out the trial, the number of unscheduled emergency
room and office or clinic visits, the change in B-type
natriuretic peptide level at six months, a newly rec-
ognized need for cardiac transplantation, and a
change in the left ventricular ejection fraction, the
left ventricular internal diastolic dimension, and the
left ventricular wall thickness at six months. Data
on patients who underwent cardiac transplantation
during the trial were censored at the time of trans-
plantation.
statistical analysis
Estimates of the sample size needed for the study to
detect significant differences in the primary com-
posite end point were based on data from V-HeFT I
and II. Since the composite measure used in this
trial had not been evaluated in previous trials, two
interim analyses were prespecified in the protocol
to permit an assessment of the adequacy of the sam-
ple size without knowledge of efficacy. The specific
techniques for assessing the adequacy of the sam-
ple size were based on methods described by Cui et
al.43 The data and safety monitoring board met four
times during the trial and conducted the prespeci-
fied interim analyses. The initial estimate that 800
patients (400 per group) were needed for the
Table 1. Scoring System for the Primary Composite End Point.
End Point Score
Death (at any time during the trial) ¡3
Survival to end of trial 0
First hospitalization for heart failure (adjudicated) ¡1
No hospitalization 0
Change in quality of life at 6 mo (or at last measurement 
if earlier than 6 mo)
Improvement by ≥10 units +2
Improvement by 5–9 units +1
Change by <5 units 0
Worsening by 5–9 units ¡1
Worsening by ≥10 units ¡2
Possible score ¡6 to +2
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study to have sufficient statistical power (P<0.02)
was modified to 1100 patients (550 per group) in
March 2003 on the basis of the prespecified inter-
im analyses.
The primary efficacy comparison included all
participants who had undergone randomization
(intention-to-treat analysis). When data were miss-
ing, the worst-case score for that component of the
composite end point was used in the primary analy-
sis. The composite end point was compared be-
tween the groups with the use of a two-sample t-test.
The three individual components of the compos-
ite end point — death from any cause, first hospi-
talization for heart failure, and a change in the qual-
ity of life — were examined separately in secondary
analyses. For the analysis of death from any cause,
we used standard Kaplan–Meier survival methods
with the log-rank test. These analyses included all
randomized patients. We compared the incidence
rates of death and of a first hospitalization for heart
failure between groups using Fisher’s exact test. We
compared the change in the quality of life between
groups using a two-sample t-test for the difference
in scores (on the basis of the data obtained at six
months or, when unavailable, data from the three-
month assessment carried forward). 
Additional descriptive statistics were estimated
for patients’ characteristics and reported as the
mean (±SD) or the total number (and percentage).
Adverse events were also compared between groups
with the use of chi-square tests.
Randomization was initiated on June 12, 2001, and
the study was terminated on July 19, 2004, on the
recommendation of the independent data and safe-
ty monitoring board after 1050 of the planned 1100
patients had undergone randomization — 518 to
receive isosorbide dinitrate plus hydralazine and
532 to receive placebo. No patients were lost to fol-
low-up.
The decision to stop the trial was based on the
Lan–DeMets sequential-boundaries calculation.44
The trial was halted owing to a significantly higher
mortality rate in the placebo group than in the group
given isosorbide dinitrate plus hydralazine. At the
time the trial was halted, 54 patients had died in the
placebo group (10.2 percent) and 32 patients had
died in the combination-therapy group (6.2 per-
cent). There was a significant 43 percent improve-
ment in survival (hazard ratio, 0.57; P=0.01 by the
log-rank test). The mean duration of follow-up was
10 months (range, 0 to 18). The Kaplan–Meier sur-
vival analysis (Fig. 1) demonstrates that survival dif-
ferences emerged at approximately 180 days and
widened progressively thereafter (P=0.01 by the log-
rank test).
The baseline clinical characteristics of the pa-
tients are shown in Table 2. At the termination of the
trial, the primary composite score was ¡0.1±1.9 in
the group given isosorbide dinitrate plus hydrala-
zine, as compared with ¡0.5±2.0 in the placebo
group (P=0.01), thus demonstrating a significant
beneficial effect of nitric oxide–enhancing therapy
(Table 3). In addition to the reduction in the rate of
death from any cause, the other individual compo-
nents of the primary composite score were also sig-
nificantly improved by treatment with isosorbide
dinitrate and hydralazine (Table 3). The rate of first
hospitalizations for heart failure was reduced by 33
percent, as compared with that in the placebo group
(16.4 percent vs. 24.4 percent; 85 patients vs. 130
patients; P=0.001). The quality-of-life scores also
improved more in the group given isosorbide dini-
trate plus hydralazine than in the placebo group
(¡5.6±20.6 vs. ¡2.7±21.2, P=0.02).
The composite end point was based on data on
1050 patients (the intention-to-treat population).
A total of 742 patients filled out the quality-of-life
questionnaire at six months. For all other patients,
either an earlier post-baseline quality-of-life score
was used or, if no such score was available, the pa-
tient received the worst possible score for the
results
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change in the quality of life (¡2) as part of the com-
posite end point. 
The target dose was achieved in 68.0 percent of
the patients in the group given isosorbide dinitrate
plus hydralazine, as compared with 88.9 percent of
the patients in the placebo group (P<0.001). The
mean number of tablets per day was 3.8±2.5 in
the group given isosorbide dinitrate plus hydrala-
zine and 4.7±2.2 in the placebo group (P<0.001).
Combination therapy had a slight but signifi-
cant blood-pressure–lowering effect at six months,
decreasing systolic blood pressure by a mean of 1.9
mm Hg, as compared with an increase of 1.2 mm Hg
in the placebo group (P=0.02), and decreasing dia-
stolic blood pressure by a mean of 2.4 mm Hg, as
compared with an increase of 0.8 mm Hg in the
placebo group (P<0.001). There was no significant
change in the heart rate between the two groups.
Adverse events are shown in Table 4. Symptoms
of headache and dizziness were significantly more
frequent in the group given isosorbide dinitrate plus
hydralazine, whereas exacerbations of congestive
heart failure (both moderate and severe) were sig-
nificantly more frequent in the placebo group.
We confirmed the findings in V-HeFT I of the effi-
cacy and survival advantage of a combination of iso-
sorbide dinitrate plus hydralazine added to standard
background therapy in patients with moderate-to-
severe heart failure. The trial population was limit-
ed to patients who identified themselves as black, a
subgroup that had had a particularly favorable re-
sponse to this therapy in retrospective analyses.6,38
The 43 percent reduction in the mortality rate in
the group given isosorbide dinitrate plus hydrala-
zine occurred among patients who were well treat-
ed with a background regimen of neurohormonal-
inhibitor drugs. Thus, the reduction in mortality is
consistent with the existence of an alternative mech-
anism controlling the progression of heart failure.
A similar reduction in mortality was previously re-
ported among blacks with NYHA class II, III, or IV
heart failure in V-HeFT I who were receiving only
diuretics and digitalis rather than neurohormonal-
inhibiting agents.6,38 These results suggest that a
fixed-dose combination of isosorbide dinitrate plus
hydralazine may benefit patients in a manner that
is independent of background therapy.
Growing evidence supports the concept that ni-
tric oxide protects against myocardial and vascular
discussion
* Plus–minus values are means ±SD. NYHA denotes New York Heart Associa-
tion, LVIDD left ventricular internal diastolic dimension, ACE angiotensin-con-
verting enzyme, and ARB angiotensin-receptor blocker. Because of rounding, 
percentages may not total 100.
† P=0.008 for the comparison with the placebo group.
‡ Data were obtained at screening.
§ P=0.01 for the comparison with the placebo group.
¶P=0.002 for the comparison with the placebo group.








Age (yr) 56.7±12.7 56.9±13.3
Male sex (% of patients) 55.8† 63.9
Weight (kg) 92.5±21.4 94.1±25.5
Primary cause of heart failure 
(% of patients)
Ischemic heart disease 23.4 22.7
Hypertension 40.0 37.4
Idiopathic 24.5 27.6
Valvular cause 2.5 3.2
Other 9.7 9.0





Diabetes (% of patients) 44.8§ 37.0
Renal insufficiency (% of patients) 16.2 18.2
 Atrial fibrillation (% of patients) 15.0 18.0
Cardiac resynchronization therapy 
(% of patients)
2.0 2.1
Implantable cardiac defibrillator 
(% of patients)
16.6 17.3
Ejection fraction (%)‡ 23.9±7.3 24.2±7.5
LVIDD (cm)‡ 6.5±0.9 6.5±1.0
Blood pressure (mm Hg)
Systolic 127.2±17.4 125.3±18.1
Diastolic 77.6±10.3¶ 75.6±10.5
Minnesota Living with Heart Failure 
Questionnaire score (range, 0 to 105)
50.9±24.9¶ 50.7±25.5
Medications for heart failure (% of patients)
Diuretic 88.0 91.5
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remodeling.11,22-27,45-47 The combination of iso-
sorbide dinitrate and hydralazine may serve as a
nitric oxide donor, with hydralazine conferring
protection against the degradation of nitric oxide
induced by oxidative stress.48-52 Thus, data from
A-HeFT support, but do not prove, the existence of
a protective role of nitric oxide even in the presence
of neurohormonal blockade.
We used two strategies to demonstrate the effi-
cacy of isosorbide dinitrate plus hydralazine as ther-
apy for heart failure in a moderate-sized cohort.
First, we designed the trial to include only patients
self-identified as black, since previous data suggest-
ed that such patients had increased responsiveness
to this therapy.6,38 Second, we used a composite
score, composed of weighted values for death from
any cause, a first adjudicated hospitalization for
heart failure, and change in the quality of life, as the
primary end point. We hypothesized that including
in the primary end point data relevant to all impor-
tant outcomes of chronic disease would enhance
the statistical power of the study to detect efficacy
in a moderate-sized cohort.53 The significant ben-
efit of isosorbide dinitrate plus hydralazine dem-
onstrated by the differences in the composite score
(¡0.1±1.9, as compared with ¡0.5±2.0 in the pla-
cebo group; P=0.01) provides support for the use
of such an end point in future trials.
Nitric oxide regulates cardiovascular processes
including myocardial hypertrophy, remodeling, and
substrate use, as well as vascular function, inflam-
mation, and thrombosis.11,22-27,45-47 Substantial
evidence exists that endothelial dysfunction and im-
paired bioavailability of nitric oxide occur in both
ischemic and nonischemic models of heart failure
and contribute to the pathophysiology of conges-
tive heart failure.12-19,21 Studies of murine models
of heart failure — mice deficient in endothelial ni-
tric oxide synthase and mice overexpressing nitric
oxide synthase — have demonstrated the role of ni-
tric oxide in preserving left ventricular performance,
inhibiting myocardial remodeling, and improving
survival.23,24,27,46 Nitric oxide has also been shown
to regulate the use of myocardial substrate47 and
mitochondrial respiration.25 In clinical models of
heart failure, basal cardiac release of nitric oxide is
decreased,54 sensitivity to inhibition of nitric oxide
synthase is increased,55 nitric oxide–mediated pro-
cesses are impaired,12,13,18 and oxidative stress is
increased.14,15,17,19,20 
Our choice of a study cohort of patients identify-
ing themselves as black is based on observations of
differences in prevalence, risk profiles, causation,
disease severity, outcomes, and response to therapy
between black patients and white patients with heart
failure.28-30 Retrospective analyses according to
race in V-HeFT I, V-HeFT II, and the Studies of Left
Ventricular Dysfunction have shown significant
differences between blacks and whites in the re-
sponse to pharmacotherapy for heart failure.30,38,39
In a novel experimental system, Kalinowski et al.37
found that, as compared with endothelial cells from
healthy white women, endothelial cells from healthy
black women had diminished bioavailability of ni-
tric oxide as a result of increased oxidative stress.
Data suggesting that endothelial function and bio-
availability of nitric oxide may be less robust in
blacks than in whites32-37 lend credibility to the hy-
pothesis that the balance of mechanisms leading
to the progression of heart failure may vary with
geographic origin. 
* Plus–minus values are means ±SD.
† Scores can range from ¡6 to 2, with higher scores indicating a better outcome.
‡ Lower scores indicate a better quality of life.








Primary composite score† ¡0.1±1.9 ¡0.5±2.0 0.01
Components of the primary com-
posite score
Death from any cause — no. (%) 32 (6.2) 54(10.2) 0.02
First hospitalization for heart
failure — no. (%)
85 (16.4) 130 (24.4) 0.001
Change in quality-of-life score
at 6 mo‡
¡5.6±20.6 ¡2.7±21.2 0.02
* CHF denotes congestive heart failure.




Hydralazine Placebo P Value
percent
Exacerbations of CHF 8.7 12.8 0.04
Severe exacerbation of CHF 3.1 7.0 0.005
Headache 47.5 19.2 <0.001
Dizziness 29.3 12.3 <0.001
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The combination of isosorbide dinitrate and hy-
dralazine was used as a vasodilator in V-HeFT I be-
cause of its balanced effect on arteriolar dilation and
venodilation. Once the physiologic role of nitric ox-
ide was elucidated, it became apparent that isosor-
bide dinitrate exerts its vasodilatory effect by donat-
ing nitric oxide or forming related compounds.48,56
Concomitant administration of hydralazine pro-
longs the vasodilatory effects of isosorbide dinitrate
in experimental and clinical models.19,49-52 Munzel
et al.51 have shown that hydralazine is an effective
antioxidant, inhibiting the generation of nitric ox-
ide–inactivating reactive oxygen species by inhibit-
ing vascular NADH and NADPH oxidases. Similarly,
other antioxidants have been shown to reduce the
mitochondrial production of reactive oxygen spe-
cies.57 Thus, hydralazine, by reducing oxidative
stress, may enhance the effects of nitric oxide de-
rived from nitric oxide donors as well as from en-
dogenous sources. This study, however, does not
establish that these mechanisms explain the clini-
cal benefit of isosorbide dinitrate plus hydralazine
in heart failure.
Our trial represents a departure from the recent
approach to the design of cardiovascular trials.
Rather than studying a large heterogeneous popu-
lation, we examined a specific population in whom
efficacy was more likely to be established. A heter-
ogeneous population may have substantial varia-
tions in genetic and environmental factors that in-
fluence disease progression and the response to
therapy. Since subgroups of the trial cohort are rare-
ly large enough for statistical analyses of the heter-
ogeneity of an effect, the standard thinking is that
the overall response to therapy should be accepted
as a mandate for the use of that therapy in all sub-
groups in the trial. Recent insights into mechanis-
tic variability, however, lend credence to the concept
that the average effects in heterogeneous popula-
tions may obscure therapeutic efficacy in some sub-
groups and the lack of such efficacy in others. 
Our finding of the efficacy of isosorbide dinitrate
plus hydralazine in black patients provides strong
evidence that this therapy can slow the progression
of heart failure. A future strategy would be to iden-
tify genotypic and phenotypic characteristics that
would transcend racial or ethnic categories to iden-
tify a population with heart failure in which there is
an increased likelihood of a favorable response to
such therapy.
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